Imaging and therapy of ovarian cancer: Clinical application of nanoparticles and future perspectives

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Despite significant advances in cancer diagnostics and treatment, ovarian cancers (OC) continue to kill more than 150,000 women every year worldwide. Due to the relatively asymptomatic nature and the advanced stage of the disease at the time of diagnosis, OC is the most lethal gynecologic malignancy. The current treatment for advanced OC relies on the synergistic effect of combining surgical cytoreduction and chemotherapy; however, beside the fact that chemotherapy resistance is a major challenge in OC management, new imaging strategies are needed to target microscopic lesions and improve both cytoreductive surgery and patient outcomes. In this context, nanostructured probes are emerging as a new class of medical tool that can simultaneously provide imaging contrast, target tumor cells, and carry a wide range of medicines resulting in better diagnosis and therapeutic precision. Herein we summarize several exemplary efforts in nanomedicine for addressing unmet clinical needs.

Original languageEnglish
Pages (from-to)4279-4294
Number of pages16
JournalTheranostics
Volume8
Issue number16
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Ovarian Neoplasms
Nanoparticles
Nanomedicine
Drug Therapy
Neoplasms
Therapeutics

Keywords

  • Imaging
  • Nanoparticles
  • Ovarian cancer
  • Surgery
  • Therapy

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

@article{c297fab0743b434f8862f2facd36e254,
title = "Imaging and therapy of ovarian cancer: Clinical application of nanoparticles and future perspectives",
abstract = "Despite significant advances in cancer diagnostics and treatment, ovarian cancers (OC) continue to kill more than 150,000 women every year worldwide. Due to the relatively asymptomatic nature and the advanced stage of the disease at the time of diagnosis, OC is the most lethal gynecologic malignancy. The current treatment for advanced OC relies on the synergistic effect of combining surgical cytoreduction and chemotherapy; however, beside the fact that chemotherapy resistance is a major challenge in OC management, new imaging strategies are needed to target microscopic lesions and improve both cytoreductive surgery and patient outcomes. In this context, nanostructured probes are emerging as a new class of medical tool that can simultaneously provide imaging contrast, target tumor cells, and carry a wide range of medicines resulting in better diagnosis and therapeutic precision. Herein we summarize several exemplary efforts in nanomedicine for addressing unmet clinical needs.",
keywords = "Imaging, Nanoparticles, Ovarian cancer, Surgery, Therapy",
author = "{Di Lorenzo}, Giovanni and Giuseppe Ricci and Severini, {Giovanni Maria} and Federico Romano and Stefania Biffi",
year = "2018",
month = "1",
day = "1",
doi = "10.7150/thno.26345",
language = "English",
volume = "8",
pages = "4279--4294",
journal = "Theranostics",
issn = "1838-7640",
publisher = "Ivyspring International Publisher",
number = "16",

}

TY - JOUR

T1 - Imaging and therapy of ovarian cancer

T2 - Clinical application of nanoparticles and future perspectives

AU - Di Lorenzo, Giovanni

AU - Ricci, Giuseppe

AU - Severini, Giovanni Maria

AU - Romano, Federico

AU - Biffi, Stefania

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Despite significant advances in cancer diagnostics and treatment, ovarian cancers (OC) continue to kill more than 150,000 women every year worldwide. Due to the relatively asymptomatic nature and the advanced stage of the disease at the time of diagnosis, OC is the most lethal gynecologic malignancy. The current treatment for advanced OC relies on the synergistic effect of combining surgical cytoreduction and chemotherapy; however, beside the fact that chemotherapy resistance is a major challenge in OC management, new imaging strategies are needed to target microscopic lesions and improve both cytoreductive surgery and patient outcomes. In this context, nanostructured probes are emerging as a new class of medical tool that can simultaneously provide imaging contrast, target tumor cells, and carry a wide range of medicines resulting in better diagnosis and therapeutic precision. Herein we summarize several exemplary efforts in nanomedicine for addressing unmet clinical needs.

AB - Despite significant advances in cancer diagnostics and treatment, ovarian cancers (OC) continue to kill more than 150,000 women every year worldwide. Due to the relatively asymptomatic nature and the advanced stage of the disease at the time of diagnosis, OC is the most lethal gynecologic malignancy. The current treatment for advanced OC relies on the synergistic effect of combining surgical cytoreduction and chemotherapy; however, beside the fact that chemotherapy resistance is a major challenge in OC management, new imaging strategies are needed to target microscopic lesions and improve both cytoreductive surgery and patient outcomes. In this context, nanostructured probes are emerging as a new class of medical tool that can simultaneously provide imaging contrast, target tumor cells, and carry a wide range of medicines resulting in better diagnosis and therapeutic precision. Herein we summarize several exemplary efforts in nanomedicine for addressing unmet clinical needs.

KW - Imaging

KW - Nanoparticles

KW - Ovarian cancer

KW - Surgery

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=85052652543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052652543&partnerID=8YFLogxK

U2 - 10.7150/thno.26345

DO - 10.7150/thno.26345

M3 - Review article

AN - SCOPUS:85052652543

VL - 8

SP - 4279

EP - 4294

JO - Theranostics

JF - Theranostics

SN - 1838-7640

IS - 16

ER -